sqi pharma business overview · 7 plex puls panel for cardiac markers completed, sqidlite installed...
TRANSCRIPT
s c i e n c e q u a l i t y i n n o v a t i o n
This presentation may contain certain statements including, without limitation, the words “may”, “plan”, “will”,“estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in the process”, “benefits”, “leading to”,“possible”, “is subject to” and other similar expressions which may constitute “forward-looking statements”within the meaning of applicable securities laws.
Forward-looking statements reflect the Company's current expectations and assumptions, and are subject to anumber of risks and uncertainties that could cause actual results to differ materially from those anticipated.Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties including, but not limited to: our ability to market and sellour products including our novel multiplexing technologies and detection platforms; our ability to maintain anytechnical or product advantages; the success of our Diagnostic Tools and Services business and our intent tobuild near-term revenue streams from this business; the successful regulatory filing and receipt of regulatoryapprovals for our later stage quantitative diagnostic kits; adverse changes in general economic conditions;international risk and currency exchange fluctuations; competitor activity; technology changes; regulatoryapprovals and the impact of healthcare reform legislation; and, SQI's ability to raise additional funds in thefuture.
Such statements, risks and uncertainties are detailed in the Company’s ongoing filings with the securitiesregulatory authorities, and are available to the public at www.sedar.com. The Company undertakes noobligation to publicly update or revise any forward-looking statements either as a result of new information,future events or otherwise, except as required by applicable securities laws.
FORWARD LOOKING STATEMENTS
2
3
BioPharma Drug Developers & Other Diagnostic Companies with novel tests
A DIAGNOSTIC TOOLS COMPANY OFFERING MULTIPLEXED DX TESTS AND AUTOMATED
SYSTEMS TO MEET THE UNMET NEEDS OF
science quality innovation
Proven multiplexing technology – more results, fewer tests run
Growing list of established diagnostics and global biopharma customers
Technical Superiority
Very high levels of customer satisfaction
ISO 13485 compliant development and manufacturing – trust
Achieving significant cost reductions in their core business
EXPERIENCED EXECUTIVE TEAM
Name Title Previous Affiliations
Andrew Morris CEO
Eric Brouwer CSO
Russ Peloquin VP, Sales & Marketing
Aye Nyein San VP Engineering
Patricia Lie VP Finance TD Canada Trust PwC
Peter Lea Founder 45 Publications; 40 Patents
BOARD OF DIRECTORS
Name Title Affiliations
Clive
BeddoeChairman
Hanover Group of Companies
Gerald
Connor
Board Member
Wilmot
MatthewsBoard Member
Claude Ricks Chairman, Audit Committee
Eric
Schneider
Board Member
Andrew
MorrisBoard Member, CEO
MULTIPLEXING
6
mul·ti·plex ---- verb ---- /‘məl-tē -, pleks/-to detect multiple analytes from a single biological specimen
one wellone unit of effortmultiple results
the pain is cost, the cure is multiplexing and automated analyzers from SQI
using only 15 minutes of labour, our products and systems deliver full panels of over 7,000 quantified results
reducing labour costs by > 90%maintaining quality and performance
in every result
7
SIGNIFICANT LABOUR AND TIME SAVINGS
Save time and reduce costs, with superior technical performance
Standard ELISA(manual operation)
sqidliteTM
50 Minutes / Patient 30 Seconds / Patient
10-X
8
SIGNIFICANT LABOUR AND TIME SAVINGS – MATH
and, the sqidlite is super easy to use
Standard ELISA(manual operation) sqidliteTM
43 plex biomarker panel
100,000 patient samples
43 samples / patient
86 if using duplicates
89,583 ELISA Kits
3,733 days of labour
1 sample / patient
no duplicates needed
1,042 SQI Kits
34 days of labour on 2 sqidlites
Focus on Two Major Dx Markets
9
40%
50%
10%
Drug Development Testing
Global Pharma
Gobal Biotech
Medium Pharma
40%
40%
10%
10%
Diagnostic Tests
Global Animal HealthDx
Human Molecular Dx
Human Protein Dx
SQD IVD -autoimmune, etc.
custom and off-the-shelf tests for drug development testing
safety & efficacy tests are large % of total R&D budgets & are addressable by SQI tech
$11B in North America
we take Dx operators’ existing single test products and multiplex them
Human and Animal Health addressable markets
Human - $4B for Dx immunoassays / $9B for Dx molecular tests in North America
Animal Health - $1B consumables market
$11B $14B
10
CURRENT CUSTOMERS & SALES FUNNEL
Customer
Count Customer Description Alternate Name / Detail Commercial Status
1 GD-Biosciences PULS 7-plex predictive panel Generating Revenue, 1 sqidlite, Second Order Shipped
2 DNA Sepsis Customer Sepsis pathogen detection Generating revenue (2 sqidlites)
3 Big Pharma PK Generating revenue (1 sqidlite under service contract)
4 Big Pharma; SQI as CRO GM-CSF Generating revenue; Prd Dev done; awaiting patient samples
5 IRX Pharma Quality Control Kits Generating review (1 sqid-X); 2 orders shipped
6 Big Biotech ; SQI as CRO ADA Generating Revenu; Prod Dev Complete; waiting for primate samples
7 Big Biotech; SQI as CRO ADA Prod Dev Complete -company sold - pause
Sales Funnel
Near Term Prospects
8 Direct to Consumer Dx Celiac / RA / Men's health Contracting
9 Partnership: Lung Transplant Dx 8-plex MDx and PoC MDx Green Light to proceed; Term Sheet and Quote pending acceptance
10 CRO Take out MSD - cytokines, ADA Work planning
Animal Dx (same customer as #2) Bovine Mastitis Selling small volumes of kits
11 Big Biotech Cytokine Samples to be sent 0x/2018
12 63X Cytokine Panel Peprotech-Stanford-SQI Work planning
13 Partnership: Lupus Nephritis Dx J Winter / 6-plex Work planning
Big Pharma (same customer as #3) Xplex / Streptavidin / NAb On hold
RECENT (CUSTOMER) ANNOUNCEMENTS
GD Biosciences PULS cardiac panel validation completed Feb 27 – their customers include Cleveland Heartlabs (acquired by Quest), LifeLabs, Cedar Sinai, and others
Global Biotech Signed – Jan 17
7 Plex PULS panel for cardiac markers completed, sqidlite installed Nov 30
Global Pharma Signed – Nov 20
Over-subscribed financing closes – Dec 20
SQI Partners with McMaster to co-develop “instant immunoassay” chip – Jul 24
SQI Diagnostics announces commercial contract with global biotechnology company – Jul 18
SQI Sells sqid-X system to IRX Therapeutics
12
5 YEAR FINANCIAL VIEW
Fiscal YE 2015 [A] 2016 [A] 2017 [A] 2018 [E] 2019 [E]
# Platforms 1 2 5+ 10+ 20+
$ millions
Revenue 0.6 1.6 1 3-4 10+
Op Expenses 6.4 5.6 6 6.5 7
Cash Flow Positive Exiting 2018
COMPANY SNAPSHOT
13
TSX-V :SQD
Traded on OTCQ :SQIDF
Shares outstanding: 135M
Warrants: 59M
Stock Options:
Market Cap: ~$24M
Insider ownership ~ 66%
24 Jun to 24 Jan trading volume = 34M
VWAP = $0.17
CONTACT INFORMATION:
SQI DIAGNOSTICS INC.
36 METEOR DRIVE
TORONTO, CANADA M9W 1A4
[email protected]/[email protected]
416-674-9500 /X229